HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys, SEC Finds Company Violated Securities Laws
SAN FRANCISCO, Oct. 2, 2020 /PRNewswire/ -- Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.
Relevant Period: Before Sept. 25, 2020
Visit: www.hbsslaw.com/investor-fraud/PGEN
Contact An Attorney Now: [email protected]
844-916-0895
Precigen, Inc. (PGEN) Investigation:
The investigation focuses on Precigen's claims about its conversion of relatively inexpensive natural gas into more expensive industrial chemicals using its methane bioconversion ("MCB") program.
The program was supposed to use low-cost natural gas as the feedstock for the conversion of methane into high value chemicals. The company intended to genetically engineer methanotrophs, organisms that consume and metabolize methane, the main component of natural gas, as their energy source to produce high value chemicals on a commercial scale through a fermentation process using natural gas as the feedstock – something that had never been done before.
On Apr. 21, 2016, Spotlight Research published a scathing report presenting the case that the company is a fraud and drawing parallels to Theranos.
On May 3, 2016, Motley Fool commented after reviewing Spotlight's 90 page report concluding, "I cannot point to a single in-house developed technical advantage that [the company] has over any of its competitors," and "[n]or can anyone in the engineered biology field because, simply put, one doesn't exist."
On May 11, 2020, Precigen disclosed the SEC served a subpoena on the company regarding its MCB program disclosures.
Finally, on Sept. 25, 2020, the SEC issued a cease and desist order against the company, finding that the company violated the federal securities laws. The SEC found the company was primarily using more expensive pure methane for the relevant laboratory experiments while telling investors that the results were achieved using natural gas.
"We're focused on investors' losses and determining whether Precigen and senior executives intentionally promoted fake technology," said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you are an Interface investor and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.
Whistleblowers: Persons with non-public information regarding Precigen should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 844-916-0895
SOURCE Hagens Berman Sobol Shapiro LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article